Literature DB >> 16799709

Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas.

Yukihiro Hiraishi1, Takeshi Wada, Ken Nakatani, Kenji Negoro, Shigeyuki Fujita.   

Abstract

Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family, which is expressed or highly expressed in a variety of solid tumors, including oral cancers. High EGFR expression has been correlated with tumor size, metastasis and survival. In recent years, EGFR has been considered a promising target for monoclonal antibody therapy. A total of 52 patients with oral squamous cell carcinoma (OSCC) were selected for EGFR and phosphorylated EGFR (p-EGFR) detection. Immunohistochemical staining was performed to evaluate EGFR and p-EGFR expression. Positive EGFR and p-EGFR staining was present in 92.3% (48/52) and 98.0% (51/52) of all cases, respectively. High EGFR and p-EGFR expression was present in 63.4% (33/52) and 69.2% (36/52) of all cases, respectively. EGFR and p-EGFR expression did not correlate with the clinical factors tumor stage, regional lymph node metastasis, or distant metastasis. However, a statistically significant correlation was identified between high EGFR expression and the pathologic factor tumor invasion. As a conclusion, the majority of OSCCs highly express EGFR and p-EGFR, indicating the importance of studying the efficacy of anticancer therapy targeting these signal factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799709     DOI: 10.1007/bf02893450

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  21 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Epidermal growth factor receptor immunoreactivity in human laryngeal squamous cell carcinoma.

Authors:  C S Lee; A Redshaw; G Boag
Journal:  Pathology       Date:  1997-08       Impact factor: 5.306

3.  Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.

Authors:  W Xia; Y K Lau; H Z Zhang; F Y Xiao; D A Johnston; A R Liu; L Li; R L Katz; M C Hung
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

4.  Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients.

Authors:  Takanori Kanematsu; Seiji Yano; Hisanori Uehara; Yoshimi Bando; Saburo Sone
Journal:  Oncol Res       Date:  2003       Impact factor: 5.574

5.  A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas.

Authors:  J H Kearsley; J H Leonard; M D Walsh; G R Wright
Journal:  Pathology       Date:  1991-07       Impact factor: 5.306

Review 6.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

Authors:  John Mendelsohn; Jose Baselga
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

7.  Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region.

Authors:  T C Putti; K F To; H C Hsu; A T C Chan; G M Lai; G Tse; Y S Lee; J Whang-Peng; M Millward; L Lin; X Lin; C S Lee
Journal:  Histopathology       Date:  2002-08       Impact factor: 5.087

8.  Autophosphorylation sites on the epidermal growth factor receptor.

Authors:  J Downward; P Parker; M D Waterfield
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

9.  Oncogenes in head and neck cancer.

Authors:  J C Irish; A Bernstein
Journal:  Laryngoscope       Date:  1993-01       Impact factor: 3.325

10.  Expression of EGF, EGFR and PCNA in laryngeal lesions.

Authors:  Q H Wen; T Nishimura; T Miwa; I Nagayama; M Furukawa
Journal:  J Laryngol Otol       Date:  1995-07       Impact factor: 1.469

View more
  22 in total

1.  IL-6/STAT3 signaling pathway is activated in plasma cell mastitis.

Authors:  Yang Liu; Jian Zhang; Yu-Hui Zhou; Yi-Na Jiang; Wei Zhang; Xiao-Jiang Tang; Yu Ren; Shui-Ping Han; Pei-Jun Liu; Jing Xu; Jian-Jun He
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer.

Authors:  James Keller; Kenneth R Shroyer; Shishir K Batajoo; Hong-Ling Zhao; Li Ming Dong; Michael J Hayman; Edward L Chan
Journal:  Cancer Invest       Date:  2010-09-27       Impact factor: 2.176

3.  pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations.

Authors:  Gabriella Aquino; Giuseppe Pannone; Angela Santoro; Giuseppina Liguori; Renato Franco; Rosario Serpico; Gianluca Florio; Alfredo De Rosa; Marilena Mattoni; Valentina Cozza; Gerardo Botti; Simona Losito; Francesco Longo; Stefania Staibano; Giovanni Cuda; Lorenzo Lo Muzio; Carolina Sbordone; Pantaleo Bufo; Anna Grimaldi; Michele Caraglia; Marina Di Domenico
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

4.  CIP2A expression and localization in oral carcinoma and dysplasia.

Authors:  Joseph Katz; Andrew Jakymiw; Monet K Ducksworth; Carol M Stewart; Indraneel Bhattacharyya; Seunghee Cha; Edward K L Chan
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

5.  EGFR inhibitor enhances cisplatin sensitivity of human glioma cells.

Authors:  Yan Zhang; Xihong Xing; Hongfeng Zhan; Qiaoyu Li; Yu Fan; Liping Zhan; Qiang Yu; Jian Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

6.  Activation of the IL-6/JAK/STAT3 signaling pathway in human middle ear cholesteatoma epithelium.

Authors:  Wei Liu; Shumin Xie; Xing Chen; Xingwang Rao; Hongmiao Ren; Bing Hu; Tuanfang Yin; Yuyan Xiang; Jihao Ren
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  Topical Application of Green Tea Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) for Prevention of Recurrent Oral Neoplastic Lesions.

Authors:  Angela J Yoon; Jing Shen; Regina M Santella; Elizabeth M Philipone; Hui-Chen Wu; Sidney B Eisig; Andrew Blitzer; Lanny G Close; David J Zegarelli
Journal:  J Orofac Sci       Date:  2012

8.  Activation of the EGFR/Akt/NF-κB/cyclinD1 survival signaling pathway in human cholesteatoma epithelium.

Authors:  Wei Liu; Tuanfang Yin; Jihao Ren; Lihua Li; Zian Xiao; Xing Chen; Dinghua Xie
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-05       Impact factor: 2.503

9.  Elevated EGF Levels in the Blood Serum of Dogs with Periodontal Diseases and Oral Tumours.

Authors:  Aleksandra Sobczyńska-Rak; Beata Żylińska; Izabela Polkowska; Tomasz Szponder
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

10.  Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A.

Authors:  Tara L Johnson; Maria B Lai; James C K Lai; Alok Bhushan
Journal:  Evid Based Complement Alternat Med       Date:  2008-02-29       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.